Research
Hormonal
GLP-1 receptor agonists (specifically semaglutide and tirzepatide) offer superior glycemic control and significant weight loss compared to other antidiabetic drugs, with tirzepatide showing potential for diabetes remission.
For type 2 diabetes, especially if you are overweight, GLP-1 agonists like semaglutide and tirzepatide are highly effective. Tirzepatide, in particular, has shown the ability to put diabetes into remission for many patients, along with significant weight loss.
StrongSupportsVERY_HIGH confidence
Tirzepatide is a synthetic peptide consisting of 39 amino acids, a dual GIP/GLP-1 receptor agonist. In the SURPASS-1 study... the proportion of patients who reached 'diabetes remission' levels with HbA1c below 5.7% and showed normal blood glucose was approximately 50% in the tirzepatide 15 mg group.
Why this rating
Based on multiple Phase 3 trials (PIONEER, STEP, SURPASS) cited.
Source
Characteristics of the Latest Therapeutic Agent for Diabetes
Nuri Yun · Journal of Korean Diabetes · 2023
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →